QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne
This article was originally published in The Pink Sheet Daily
Executive Summary
Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.